Renal protection during 177lutetium DOTATATE molecular radiotherapy in children: a proposal for safe amino acid infusional volume during peptide receptor radionuclide therapy-Reference-Cited by-同舟云学术

Renal protection during 177lutetium DOTATATE molecular radiotherapy in children: a proposal for safe amino acid infusional volume during peptide receptor radionuclide therapy

Published:2021-10-20 Issue:2 Volume:43 Page:242-246
ISSN:0143-3636
Container-title:Nuclear Medicine Communications
language:en
Short-container-title:

Author:

Taylor Catherine A.,Shankar Ananth,Gaze Mark N.,Peet Connie,Gains Jennifer E.,Wan Simon,Voo Stefan,Priftakis Dimitrios,Bomanji Jamshed B.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Radiology, Nuclear Medicine and imaging,General Medicine

Reference27 articles.

1. (123)I-mIBG scintigraphy in patients with known or suspected neuroblastoma: results from a prospective multicenter trial.;Vik;Pediatr Blood Cancer,2009

2. 123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma.;Bleeker;Cochrane Database Syst Rev,2015

3. A phase IIa trial of molecular radiotherapy with 177-lutetium DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma.;Gains;Eur J Nucl Med Mol Imaging,2020

4. 177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma.;Gains;J Nucl Med,2011

5. Prevalence and clinical correlations of somatostatin receptor-2 (SSTR2) expression in neuroblastoma.;Alexander;J Pediatr Hematol Oncol,2019

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DNA-encoded chemical libraries enable the discovery of potent PSMA-ligands with substantially reduced affinity towards the GCPIII anti-target;Chemical Science;2024

2. Current Status and Future Perspective on Molecular Imaging and Treatment of Neuroblastoma;Seminars in Nuclear Medicine;2023-07

3. Cross-reactivity to glutamate carboxypeptidase III causes undesired salivary gland and kidney uptake of PSMA-targeted small-molecule radionuclide therapeutics;European Journal of Nuclear Medicine and Molecular Imaging;2022-10-03

4. A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma–LuDO-N;Frontiers in Pediatrics;2022-03-10